We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Ambrx Biopharma Inc in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 68 → 0 (-68)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $913M → $0 (-$913M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 68

Holders
–
Holders Change
-68
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
68
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
-$238M
2
CAM
Cormorant Asset Management
Massachusetts
-$160M
3
PBA
Paradigm Biocapital Advisors
New York
-$62M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$60.4M
5
DTC
Deep Track Capital
Connecticut
-$52.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
51
Virtu Financial
New York
– -$290K -20,386 Closed
Citigroup
52
Citigroup
New York
– -$267K -18,774 Closed
BCM
53
Bayesian Capital Management
New York
– -$225K -15,804 Closed
Squarepoint
54
Squarepoint
New York
– -$220K -15,470 Closed
OWP
55
Old Well Partners
North Carolina
– -$205K -14,400 Closed
EGM
56
Engineers Gate Manager
New York
– -$176K -12,388 Closed
JP Morgan Chase
57
JP Morgan Chase
New York
– -$175K -12,312 Closed
Tudor Investment Corp
58
Tudor Investment Corp
Connecticut
– -$154K -10,800 Closed
MFS
59
Mirabella Financial Services
United Kingdom
– -$143K -10,040 Closed
Simplex Trading
60
Simplex Trading
Illinois
– -$109K -7,657 Closed
CUAMC
61
China Universal Asset Management Company
China
– -$104K -7,303 Closed
VEA
62
Virtus ETF Advisers
New York
– -$97.9K -6,878 Closed
TRCT
63
Tower Research Capital (TRC)
New York
– -$79.9K -5,614 Closed
UBS Group
64
UBS Group
Switzerland
– -$54.7K -3,840 Closed
CG
65
Cutler Group
California
– -$33K -2,380 Closed
US Bancorp
66
US Bancorp
Minnesota
– -$12.9K -906 Closed
GI
67
GAMMA Investing
California
– -$13.7K -491 Closed
Daiwa Securities Group
68
Daiwa Securities Group
Japan
– -$4K -258 Closed
1 2
3

AMAM Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2024, worth a combined $0 — down 100% from $913M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of AMAM and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Darwin Global Management, exiting entirely with an estimated $238M sold.

  • 0 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2024, down from 68 in Q4 2023.
  • Funds reported $0 of Ambrx Biopharma Inc stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Ambrx Biopharma Inc positions in Q1 2024 and 68 closed out, a net change of -68 holders.
  • The largest Ambrx Biopharma Inc seller in Q1 2024 was Darwin Global Management, an estimated $238M sold.

Based on aggregated 13F filings for Q1 2024.